Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials
Conclusion:
Neoadjuvant therapy can be offered as an acceptable standard of care for patients with purely resectable PDAC. Future research with the advances of precision oncology should now focus on the definition of the optimal regimen.
Source: Annals of Surgery - Category: Surgery Tags: ESA PAPERS Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Study | Surgery | Toxicology